Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-09-04

AUTHORS

Paolo A. Ascierto, Sanjiv S. Agarwala, Christian Blank, Corrado Caracò, Richard D. Carvajal, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S. Lo, Amanda W. Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I. Poulikakos, Sergio A. Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, Magdalena Thurin

ABSTRACT

Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic theràapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients. More... »

PAGES

391

References to SciGraph publications

  • 2016-02-02. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis in NATURE COMMUNICATIONS
  • 2021-02-08. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) in NATURE MEDICINE
  • 2021-03-31. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2021-02-18. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial in NATURE MEDICINE
  • 2013-09-18. Innate and adaptive immune cells in the tumor microenvironment in NATURE IMMUNOLOGY
  • 2017-03-27. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer in NATURE MEDICINE
  • 2021-02-08. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma in NATURE MEDICINE
  • 2017-02-24. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2021-05-20. Interpretation of T cell states from single-cell transcriptomics data using reference atlases in NATURE COMMUNICATIONS
  • 2013-12-01. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis in BMC CANCER
  • 2020-10-21. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2018-04-05. Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-12-17. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2019-11-20. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2021-04-07. Cell-programmed nutrient partitioning in the tumour microenvironment in NATURE
  • 2021-07-08. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade in NATURE MEDICINE
  • 2021-10-18. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer in NATURE BIOTECHNOLOGY
  • 2020-11-09. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity in NATURE CANCER
  • 2019-01-23. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity in NATURE
  • 2018-05-08. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2018-02-27. Defective HLA class I antigen processing machinery in cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • Journal

    TITLE

    Journal of Translational Medicine

    ISSUE

    1

    VOLUME

    20

    Author Affiliations

  • Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS “Fondazione G. Pascale”, Naples, Italy
  • Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA
  • Netherlands Cancer Institute, Amsterdam, Netherlands
  • Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori “Fondazione Pascale” IRCCS, Naples, Italy
  • Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
  • Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA
  • Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  • Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA
  • Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA
  • Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany
  • Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France
  • Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA
  • New York Grossman School of Medicine, New York University Langone, New York, NY, USA
  • Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
  • Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA
  • Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy
  • Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
  • New York University Langone Medical Center, New York, NY, USA
  • UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland
  • Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA
  • Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK
  • Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA
  • Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
  • Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12967-022-03592-4

    DOI

    http://dx.doi.org/10.1186/s12967-022-03592-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1150751238

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/36058945


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "COVID-19", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Italy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pandemics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Microenvironment", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS \u201cFondazione G. Pascale\u201d, Naples, Italy", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS \u201cFondazione G. Pascale\u201d, Naples, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ascierto", 
            "givenName": "Paolo A.", 
            "id": "sg:person.01212502023.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.264727.2", 
              "name": [
                "Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Agarwala", 
            "givenName": "Sanjiv S.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Netherlands Cancer Institute, Amsterdam, Netherlands", 
              "id": "http://www.grid.ac/institutes/grid.430814.a", 
              "name": [
                "Netherlands Cancer Institute, Amsterdam, Netherlands"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Blank", 
            "givenName": "Christian", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori \u201cFondazione Pascale\u201d IRCCS, Naples, Italy", 
              "id": "http://www.grid.ac/institutes/grid.508451.d", 
              "name": [
                "Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori \u201cFondazione Pascale\u201d IRCCS, Naples, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carac\u00f2", 
            "givenName": "Corrado", 
            "id": "sg:person.016255602354.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016255602354.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carvajal", 
            "givenName": "Richard D.", 
            "id": "sg:person.0726366600.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA", 
              "id": "http://www.grid.ac/institutes/grid.48336.3a", 
              "name": [
                "Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ernstoff", 
            "givenName": "Marc S.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA", 
              "id": "http://www.grid.ac/institutes/grid.32224.35", 
              "name": [
                "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ferrone", 
            "givenName": "Soldano", 
            "id": "sg:person.01261361112.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261361112.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA", 
              "id": "http://www.grid.ac/institutes/grid.240531.1", 
              "name": [
                "Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fox", 
            "givenName": "Bernard A.", 
            "id": "sg:person.01273025305.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273025305.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA", 
              "id": "http://www.grid.ac/institutes/grid.170205.1", 
              "name": [
                "Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gajewski", 
            "givenName": "Thomas F.", 
            "id": "sg:person.01060637247.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060637247.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garbe", 
            "givenName": "Claus", 
            "id": "sg:person.01221773122.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221773122.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France", 
              "id": "http://www.grid.ac/institutes/grid.411266.6", 
              "name": [
                "Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grob", 
            "givenName": "Jean-Jacques", 
            "id": "sg:person.011671114717.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011671114717.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.488730.0", 
              "name": [
                "Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hamid", 
            "givenName": "Omid", 
            "id": "sg:person.0575703507.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "New York Grossman School of Medicine, New York University Langone, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.137628.9", 
              "name": [
                "New York Grossman School of Medicine, New York University Langone, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Krogsgaard", 
            "givenName": "Michelle", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.19006.3e", 
              "name": [
                "Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lo", 
            "givenName": "Roger S.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.137628.9", 
              "name": [
                "Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lund", 
            "givenName": "Amanda W.", 
            "id": "sg:person.0646653121.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646653121.67"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, Naples, Italy", 
              "id": "http://www.grid.ac/institutes/grid.508451.d", 
              "name": [
                "Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, Naples, Italy"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Madonna", 
            "givenName": "Gabriele", 
            "id": "sg:person.01065052737.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065052737.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.8515.9", 
              "name": [
                "Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Michielin", 
            "givenName": "Olivier", 
            "id": "sg:person.0721745566.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721745566.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium", 
              "id": "http://www.grid.ac/institutes/grid.411326.3", 
              "name": [
                "Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Neyns", 
            "givenName": "Bart", 
            "id": "sg:person.0576756400.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576756400.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "New York University Langone Medical Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.240324.3", 
              "name": [
                "New York University Langone Medical Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Osman", 
            "givenName": "Iman", 
            "id": "sg:person.01150613333.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150613333.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Peters", 
            "givenName": "Solange", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.516104.7", 
              "name": [
                "Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Poulikakos", 
            "givenName": "Poulikos I.", 
            "id": "sg:person.01226351546.62", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226351546.62"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK", 
              "id": "http://www.grid.ac/institutes/grid.83440.3b", 
              "name": [
                "Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Quezada", 
            "givenName": "Sergio A.", 
            "id": "sg:person.0636343635.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636343635.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA", 
              "id": "http://www.grid.ac/institutes/grid.152326.1", 
              "name": [
                "Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Reinfeld", 
            "givenName": "Bradley", 
            "id": "sg:person.0773073433.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773073433.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zitvogel", 
            "givenName": "Laurence", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Puzanov", 
            "givenName": "Igor", 
            "id": "sg:person.0640153517.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA", 
              "id": "http://www.grid.ac/institutes/grid.48336.3a", 
              "name": [
                "Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Thurin", 
            "givenName": "Magdalena", 
            "id": "sg:person.01207167603.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207167603.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/s43018-020-00133-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1132441751", 
              "https://doi.org/10.1038/s43018-020-00133-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12967-020-02573-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1131947293", 
              "https://doi.org/10.1186/s12967-020-02573-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12967-021-02798-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136806668", 
              "https://doi.org/10.1186/s12967-021-02798-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-019-0771-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123477510", 
              "https://doi.org/10.1186/s40425-019-0771-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ni.2703", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009839834", 
              "https://doi.org/10.1038/ni.2703"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41591-020-01224-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1135436665", 
              "https://doi.org/10.1038/s41591-020-01224-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-018-2169-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103849539", 
              "https://doi.org/10.1007/s00262-018-2169-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-018-2131-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101243015", 
              "https://doi.org/10.1007/s00262-018-2131-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41467-021-23324-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138205161", 
              "https://doi.org/10.1038/s41467-021-23324-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41586-021-03442-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136982540", 
              "https://doi.org/10.1038/s41586-021-03442-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.4308", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084129252", 
              "https://doi.org/10.1038/nm.4308"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41586-019-0878-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111628922", 
              "https://doi.org/10.1038/s41586-019-0878-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41591-021-01406-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1139508327", 
              "https://doi.org/10.1038/s41591-021-01406-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms10391", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037507717", 
              "https://doi.org/10.1038/ncomms10391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2407-13-564", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048277702", 
              "https://doi.org/10.1186/1471-2407-13-564"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41591-020-01188-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1135200513", 
              "https://doi.org/10.1038/s41591-020-01188-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41587-021-01021-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141957771", 
              "https://doi.org/10.1038/s41587-021-01021-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41591-020-01211-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1135201485", 
              "https://doi.org/10.1038/s41591-020-01211-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-017-1968-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083869140", 
              "https://doi.org/10.1007/s00262-017-1968-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-018-0331-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103128553", 
              "https://doi.org/10.1186/s40425-018-0331-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-019-0786-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1122758482", 
              "https://doi.org/10.1186/s40425-019-0786-7"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-09-04", 
        "datePublishedReg": "2022-09-04", 
        "description": "Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic ther\u00e0apies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12967-022-03592-4", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1032886", 
            "issn": [
              "1479-5876"
            ], 
            "name": "Journal of Translational Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "20"
          }
        ], 
        "keywords": [
          "advanced melanoma", 
          "immune response", 
          "combination treatment", 
          "pre-treatment tumor biopsies", 
          "tumor microenvironment", 
          "tumor immune evasion mechanisms", 
          "immune checkpoint inhibitors", 
          "selection of patients", 
          "adoptive cell therapy", 
          "immune evasion mechanisms", 
          "host immune response", 
          "novel biomarker platform", 
          "optimize treatment regimens", 
          "prediction of response", 
          "mechanism of action", 
          "Melanoma Bridge", 
          "immunotherapy agents", 
          "checkpoint inhibitors", 
          "overall survival", 
          "adverse events", 
          "immune checkpoints", 
          "tumor immunity", 
          "local therapy", 
          "melanoma patients", 
          "treatment regimens", 
          "combination therapy", 
          "tumor biopsies", 
          "combination modality", 
          "immune features", 
          "therapeutic modalities", 
          "specific treatment", 
          "melanoma therapeutics", 
          "biomarker strategies", 
          "patients", 
          "Drug Administration", 
          "therapeutic resistance", 
          "therapy", 
          "melanoma", 
          "oncogenic viruses", 
          "robust biomarkers", 
          "clinical research", 
          "cell therapy", 
          "therapeutic agents", 
          "melanocytic lesions", 
          "biomarker platform", 
          "translational research", 
          "precision medicine", 
          "COVID-19 pandemic", 
          "treatment", 
          "improved understanding", 
          "biomarkers", 
          "meeting discussions", 
          "meeting report", 
          "modalities", 
          "microenvironment", 
          "response", 
          "predictive accuracy", 
          "regimens", 
          "chemotherapy", 
          "biopsy", 
          "radiotherapy", 
          "vaccine", 
          "tumors", 
          "lesions", 
          "agents", 
          "cancer", 
          "future research efforts", 
          "diagnosis", 
          "administration", 
          "immunity", 
          "electrochemotherapy", 
          "efficacy", 
          "survival", 
          "virus", 
          "therapeutics", 
          "inhibitors", 
          "report", 
          "mechanism", 
          "medicine", 
          "resistance", 
          "pandemic", 
          "correct classification", 
          "advances", 
          "evidence", 
          "management", 
          "strategies", 
          "action", 
          "checkpoint", 
          "events", 
          "different strategies", 
          "improvement", 
          "research efforts", 
          "real challenge", 
          "understanding", 
          "diagnostics", 
          "novel approach", 
          "addition", 
          "development", 
          "research", 
          "classification", 
          "selection", 
          "impact", 
          "features", 
          "progress", 
          "challenges", 
          "approach", 
          "efforts", 
          "aspects", 
          "new approach", 
          "discussion", 
          "perspective", 
          "accuracy", 
          "prediction", 
          "platform", 
          "bridge", 
          "algorithm"
        ], 
        "name": "Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd \u2013 4th, 2021, Italy)", 
        "pagination": "391", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1150751238"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12967-022-03592-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "36058945"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12967-022-03592-4", 
          "https://app.dimensions.ai/details/publication/pub.1150751238"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:44", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_940.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12967-022-03592-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12967-022-03592-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12967-022-03592-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12967-022-03592-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12967-022-03592-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    534 TRIPLES      21 PREDICATES      171 URIs      141 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12967-022-03592-4 schema:about N089b9e6f9c5945228aa6f9cef16df71d
    2 N09a43a6f99304755abc0eb433806010e
    3 N32dc431806ca4fe3a7ce4d1c976c647a
    4 N34326b953600423597cededcdf71aeaa
    5 N865cbe4383974941a221eb59d90890b4
    6 N8a06a7f48a50457994b96e106817e6a6
    7 Ndd18b65855844282a6daf7b9d339f8b4
    8 Ndfbc71ac08234e96983751b6231c66ac
    9 anzsrc-for:11
    10 anzsrc-for:1107
    11 anzsrc-for:1112
    12 schema:author N303a2ace54014fbb8f31fad15ee5287b
    13 schema:citation sg:pub.10.1007/s00262-017-1968-0
    14 sg:pub.10.1007/s00262-018-2131-2
    15 sg:pub.10.1007/s00262-018-2169-1
    16 sg:pub.10.1038/ncomms10391
    17 sg:pub.10.1038/ni.2703
    18 sg:pub.10.1038/nm.4308
    19 sg:pub.10.1038/s41467-021-23324-4
    20 sg:pub.10.1038/s41586-019-0878-z
    21 sg:pub.10.1038/s41586-021-03442-1
    22 sg:pub.10.1038/s41587-021-01021-3
    23 sg:pub.10.1038/s41591-020-01188-3
    24 sg:pub.10.1038/s41591-020-01211-7
    25 sg:pub.10.1038/s41591-020-01224-2
    26 sg:pub.10.1038/s41591-021-01406-6
    27 sg:pub.10.1038/s43018-020-00133-0
    28 sg:pub.10.1186/1471-2407-13-564
    29 sg:pub.10.1186/s12967-020-02573-9
    30 sg:pub.10.1186/s12967-021-02798-2
    31 sg:pub.10.1186/s40425-018-0331-0
    32 sg:pub.10.1186/s40425-019-0771-1
    33 sg:pub.10.1186/s40425-019-0786-7
    34 schema:datePublished 2022-09-04
    35 schema:datePublishedReg 2022-09-04
    36 schema:description Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic theràapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients.
    37 schema:genre article
    38 schema:isAccessibleForFree true
    39 schema:isPartOf N8c744bbe9f5b43128d68372ddf00d5fb
    40 Nec0412bc50324874880951c934d29384
    41 sg:journal.1032886
    42 schema:keywords COVID-19 pandemic
    43 Drug Administration
    44 Melanoma Bridge
    45 accuracy
    46 action
    47 addition
    48 administration
    49 adoptive cell therapy
    50 advanced melanoma
    51 advances
    52 adverse events
    53 agents
    54 algorithm
    55 approach
    56 aspects
    57 biomarker platform
    58 biomarker strategies
    59 biomarkers
    60 biopsy
    61 bridge
    62 cancer
    63 cell therapy
    64 challenges
    65 checkpoint
    66 checkpoint inhibitors
    67 chemotherapy
    68 classification
    69 clinical research
    70 combination modality
    71 combination therapy
    72 combination treatment
    73 correct classification
    74 development
    75 diagnosis
    76 diagnostics
    77 different strategies
    78 discussion
    79 efficacy
    80 efforts
    81 electrochemotherapy
    82 events
    83 evidence
    84 features
    85 future research efforts
    86 host immune response
    87 immune checkpoint inhibitors
    88 immune checkpoints
    89 immune evasion mechanisms
    90 immune features
    91 immune response
    92 immunity
    93 immunotherapy agents
    94 impact
    95 improved understanding
    96 improvement
    97 inhibitors
    98 lesions
    99 local therapy
    100 management
    101 mechanism
    102 mechanism of action
    103 medicine
    104 meeting discussions
    105 meeting report
    106 melanocytic lesions
    107 melanoma
    108 melanoma patients
    109 melanoma therapeutics
    110 microenvironment
    111 modalities
    112 new approach
    113 novel approach
    114 novel biomarker platform
    115 oncogenic viruses
    116 optimize treatment regimens
    117 overall survival
    118 pandemic
    119 patients
    120 perspective
    121 platform
    122 pre-treatment tumor biopsies
    123 precision medicine
    124 prediction
    125 prediction of response
    126 predictive accuracy
    127 progress
    128 radiotherapy
    129 real challenge
    130 regimens
    131 report
    132 research
    133 research efforts
    134 resistance
    135 response
    136 robust biomarkers
    137 selection
    138 selection of patients
    139 specific treatment
    140 strategies
    141 survival
    142 therapeutic agents
    143 therapeutic modalities
    144 therapeutic resistance
    145 therapeutics
    146 therapy
    147 translational research
    148 treatment
    149 treatment regimens
    150 tumor biopsies
    151 tumor immune evasion mechanisms
    152 tumor immunity
    153 tumor microenvironment
    154 tumors
    155 understanding
    156 vaccine
    157 virus
    158 schema:name Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
    159 schema:pagination 391
    160 schema:productId N01b5fa6ec76144b594bad30a7c2c8ebe
    161 N175a5eb2c54e4c6b9d855d47621f8136
    162 Nea1f37847dc24fee866dc77eb341e30e
    163 schema:sameAs https://app.dimensions.ai/details/publication/pub.1150751238
    164 https://doi.org/10.1186/s12967-022-03592-4
    165 schema:sdDatePublished 2022-12-01T06:44
    166 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    167 schema:sdPublisher N33fb309d10054b88ba5bcd9dfd711f7a
    168 schema:url https://doi.org/10.1186/s12967-022-03592-4
    169 sgo:license sg:explorer/license/
    170 sgo:sdDataset articles
    171 rdf:type schema:ScholarlyArticle
    172 N01b5fa6ec76144b594bad30a7c2c8ebe schema:name pubmed_id
    173 schema:value 36058945
    174 rdf:type schema:PropertyValue
    175 N03842da1de4a4d6eb5378cfc055fd2c1 rdf:first sg:person.0646653121.67
    176 rdf:rest N3f1326741f1a401b97b3da19a7af6e17
    177 N089b9e6f9c5945228aa6f9cef16df71d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Tumor Microenvironment
    179 rdf:type schema:DefinedTerm
    180 N09a43a6f99304755abc0eb433806010e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Italy
    182 rdf:type schema:DefinedTerm
    183 N0d4783572161498db1b082a4687e05ee rdf:first N9ec4c1ce0a11423589fef1959f12a03c
    184 rdf:rest Ne1ab10f10aa247b3847e641ffc9261c4
    185 N151f6c18c3da48b9a4fc34a1046706e9 schema:affiliation grid-institutes:grid.430814.a
    186 schema:familyName Blank
    187 schema:givenName Christian
    188 rdf:type schema:Person
    189 N16fe1ed9741e4fbe99336d3f38ad3400 rdf:first sg:person.0773073433.54
    190 rdf:rest Nd69f02ff0569412c8d7db534c1d22302
    191 N175a5eb2c54e4c6b9d855d47621f8136 schema:name doi
    192 schema:value 10.1186/s12967-022-03592-4
    193 rdf:type schema:PropertyValue
    194 N2bf1ad8df6b241149ccb2e02a448a49e rdf:first sg:person.011671114717.29
    195 rdf:rest Ne5917f50661e42cfbc0681aef02012ac
    196 N303a2ace54014fbb8f31fad15ee5287b rdf:first sg:person.01212502023.44
    197 rdf:rest N8efef01ebc924c1781b57b7529859990
    198 N32dc431806ca4fe3a7ce4d1c976c647a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Melanoma
    200 rdf:type schema:DefinedTerm
    201 N32fa12c97eed483baca2df8263953aa5 rdf:first sg:person.016255602354.24
    202 rdf:rest Ne4b6ef1ec580476a971109d2b6a65ff0
    203 N338e558ead3e42829a7eb81ad82308f6 rdf:first sg:person.01221773122.43
    204 rdf:rest N2bf1ad8df6b241149ccb2e02a448a49e
    205 N33fb309d10054b88ba5bcd9dfd711f7a schema:name Springer Nature - SN SciGraph project
    206 rdf:type schema:Organization
    207 N34326b953600423597cededcdf71aeaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    208 schema:name Immunotherapy
    209 rdf:type schema:DefinedTerm
    210 N364378bca0624bdf902760611c346e75 rdf:first N6c5b9c53b0e047b292a1def086ed811c
    211 rdf:rest Nd8ed015a783d4fe19a967a0329a372c8
    212 N3f1326741f1a401b97b3da19a7af6e17 rdf:first sg:person.01065052737.35
    213 rdf:rest Ned16a14813ec465384b4c2d40260758d
    214 N3f2e1a9ef9c7468b89c60963db23facb rdf:first Nd400d0da86f34242a2c5ec97b6eafe30
    215 rdf:rest N03842da1de4a4d6eb5378cfc055fd2c1
    216 N5f2e4ff373fc43e2a77e33384aea0fc5 rdf:first sg:person.01273025305.98
    217 rdf:rest N7d40fa63e5ea4edba5fc7216221528ed
    218 N6c5b9c53b0e047b292a1def086ed811c schema:affiliation grid-institutes:grid.48336.3a
    219 schema:familyName Ernstoff
    220 schema:givenName Marc S.
    221 rdf:type schema:Person
    222 N71eff240c1f6454ba555b164af05d984 rdf:first sg:person.01150613333.44
    223 rdf:rest N0d4783572161498db1b082a4687e05ee
    224 N7d40fa63e5ea4edba5fc7216221528ed rdf:first sg:person.01060637247.03
    225 rdf:rest N338e558ead3e42829a7eb81ad82308f6
    226 N865cbe4383974941a221eb59d90890b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    227 schema:name Pandemics
    228 rdf:type schema:DefinedTerm
    229 N8a06a7f48a50457994b96e106817e6a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    230 schema:name COVID-19
    231 rdf:type schema:DefinedTerm
    232 N8c744bbe9f5b43128d68372ddf00d5fb schema:issueNumber 1
    233 rdf:type schema:PublicationIssue
    234 N8efef01ebc924c1781b57b7529859990 rdf:first Nfaa6d1b963534c88bf5a67c96ef31257
    235 rdf:rest N9741b9bbad7d4957a5984ba6357ef7e1
    236 N9741b9bbad7d4957a5984ba6357ef7e1 rdf:first N151f6c18c3da48b9a4fc34a1046706e9
    237 rdf:rest N32fa12c97eed483baca2df8263953aa5
    238 N9a0066114130491391e237278f4007e2 schema:affiliation grid-institutes:None
    239 schema:familyName Zitvogel
    240 schema:givenName Laurence
    241 rdf:type schema:Person
    242 N9ec4c1ce0a11423589fef1959f12a03c schema:affiliation grid-institutes:grid.9851.5
    243 schema:familyName Peters
    244 schema:givenName Solange
    245 rdf:type schema:Person
    246 Na2e05b36e79c46e5bfcf484a743be9b1 rdf:first sg:person.0640153517.24
    247 rdf:rest Nbad98f3e346443458216e240d3dbdc4d
    248 Nbad98f3e346443458216e240d3dbdc4d rdf:first sg:person.01207167603.25
    249 rdf:rest rdf:nil
    250 Nc4ddb1d60fa145df8a44fb2fe702cf32 rdf:first Nca762218ee0b43eab52ba2d0787662be
    251 rdf:rest N3f2e1a9ef9c7468b89c60963db23facb
    252 Nca762218ee0b43eab52ba2d0787662be schema:affiliation grid-institutes:grid.137628.9
    253 schema:familyName Krogsgaard
    254 schema:givenName Michelle
    255 rdf:type schema:Person
    256 Nd383383f44004dcb9a9a2bc43276388e rdf:first sg:person.0576756400.18
    257 rdf:rest N71eff240c1f6454ba555b164af05d984
    258 Nd400d0da86f34242a2c5ec97b6eafe30 schema:affiliation grid-institutes:grid.19006.3e
    259 schema:familyName Lo
    260 schema:givenName Roger S.
    261 rdf:type schema:Person
    262 Nd69f02ff0569412c8d7db534c1d22302 rdf:first N9a0066114130491391e237278f4007e2
    263 rdf:rest Na2e05b36e79c46e5bfcf484a743be9b1
    264 Nd8ed015a783d4fe19a967a0329a372c8 rdf:first sg:person.01261361112.98
    265 rdf:rest N5f2e4ff373fc43e2a77e33384aea0fc5
    266 Ndd18b65855844282a6daf7b9d339f8b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    267 schema:name Biomarkers
    268 rdf:type schema:DefinedTerm
    269 Ndfbc71ac08234e96983751b6231c66ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    270 schema:name Humans
    271 rdf:type schema:DefinedTerm
    272 Ne1ab10f10aa247b3847e641ffc9261c4 rdf:first sg:person.01226351546.62
    273 rdf:rest Nf31308dc79bc47ac8b1eb3f11a3f8daa
    274 Ne4b6ef1ec580476a971109d2b6a65ff0 rdf:first sg:person.0726366600.25
    275 rdf:rest N364378bca0624bdf902760611c346e75
    276 Ne5917f50661e42cfbc0681aef02012ac rdf:first sg:person.0575703507.41
    277 rdf:rest Nc4ddb1d60fa145df8a44fb2fe702cf32
    278 Nea1f37847dc24fee866dc77eb341e30e schema:name dimensions_id
    279 schema:value pub.1150751238
    280 rdf:type schema:PropertyValue
    281 Nec0412bc50324874880951c934d29384 schema:volumeNumber 20
    282 rdf:type schema:PublicationVolume
    283 Ned16a14813ec465384b4c2d40260758d rdf:first sg:person.0721745566.51
    284 rdf:rest Nd383383f44004dcb9a9a2bc43276388e
    285 Nf31308dc79bc47ac8b1eb3f11a3f8daa rdf:first sg:person.0636343635.43
    286 rdf:rest N16fe1ed9741e4fbe99336d3f38ad3400
    287 Nfaa6d1b963534c88bf5a67c96ef31257 schema:affiliation grid-institutes:grid.264727.2
    288 schema:familyName Agarwala
    289 schema:givenName Sanjiv S.
    290 rdf:type schema:Person
    291 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    292 schema:name Medical and Health Sciences
    293 rdf:type schema:DefinedTerm
    294 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    295 schema:name Immunology
    296 rdf:type schema:DefinedTerm
    297 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    298 schema:name Oncology and Carcinogenesis
    299 rdf:type schema:DefinedTerm
    300 sg:journal.1032886 schema:issn 1479-5876
    301 schema:name Journal of Translational Medicine
    302 schema:publisher Springer Nature
    303 rdf:type schema:Periodical
    304 sg:person.01060637247.03 schema:affiliation grid-institutes:grid.170205.1
    305 schema:familyName Gajewski
    306 schema:givenName Thomas F.
    307 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060637247.03
    308 rdf:type schema:Person
    309 sg:person.01065052737.35 schema:affiliation grid-institutes:grid.508451.d
    310 schema:familyName Madonna
    311 schema:givenName Gabriele
    312 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065052737.35
    313 rdf:type schema:Person
    314 sg:person.01150613333.44 schema:affiliation grid-institutes:grid.240324.3
    315 schema:familyName Osman
    316 schema:givenName Iman
    317 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150613333.44
    318 rdf:type schema:Person
    319 sg:person.011671114717.29 schema:affiliation grid-institutes:grid.411266.6
    320 schema:familyName Grob
    321 schema:givenName Jean-Jacques
    322 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011671114717.29
    323 rdf:type schema:Person
    324 sg:person.01207167603.25 schema:affiliation grid-institutes:grid.48336.3a
    325 schema:familyName Thurin
    326 schema:givenName Magdalena
    327 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207167603.25
    328 rdf:type schema:Person
    329 sg:person.01212502023.44 schema:affiliation grid-institutes:None
    330 schema:familyName Ascierto
    331 schema:givenName Paolo A.
    332 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212502023.44
    333 rdf:type schema:Person
    334 sg:person.01221773122.43 schema:affiliation grid-institutes:None
    335 schema:familyName Garbe
    336 schema:givenName Claus
    337 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221773122.43
    338 rdf:type schema:Person
    339 sg:person.01226351546.62 schema:affiliation grid-institutes:grid.516104.7
    340 schema:familyName Poulikakos
    341 schema:givenName Poulikos I.
    342 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226351546.62
    343 rdf:type schema:Person
    344 sg:person.01261361112.98 schema:affiliation grid-institutes:grid.32224.35
    345 schema:familyName Ferrone
    346 schema:givenName Soldano
    347 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261361112.98
    348 rdf:type schema:Person
    349 sg:person.01273025305.98 schema:affiliation grid-institutes:grid.240531.1
    350 schema:familyName Fox
    351 schema:givenName Bernard A.
    352 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273025305.98
    353 rdf:type schema:Person
    354 sg:person.016255602354.24 schema:affiliation grid-institutes:grid.508451.d
    355 schema:familyName Caracò
    356 schema:givenName Corrado
    357 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016255602354.24
    358 rdf:type schema:Person
    359 sg:person.0575703507.41 schema:affiliation grid-institutes:grid.488730.0
    360 schema:familyName Hamid
    361 schema:givenName Omid
    362 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41
    363 rdf:type schema:Person
    364 sg:person.0576756400.18 schema:affiliation grid-institutes:grid.411326.3
    365 schema:familyName Neyns
    366 schema:givenName Bart
    367 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576756400.18
    368 rdf:type schema:Person
    369 sg:person.0636343635.43 schema:affiliation grid-institutes:grid.83440.3b
    370 schema:familyName Quezada
    371 schema:givenName Sergio A.
    372 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636343635.43
    373 rdf:type schema:Person
    374 sg:person.0640153517.24 schema:affiliation grid-institutes:grid.240614.5
    375 schema:familyName Puzanov
    376 schema:givenName Igor
    377 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640153517.24
    378 rdf:type schema:Person
    379 sg:person.0646653121.67 schema:affiliation grid-institutes:grid.137628.9
    380 schema:familyName Lund
    381 schema:givenName Amanda W.
    382 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646653121.67
    383 rdf:type schema:Person
    384 sg:person.0721745566.51 schema:affiliation grid-institutes:grid.8515.9
    385 schema:familyName Michielin
    386 schema:givenName Olivier
    387 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721745566.51
    388 rdf:type schema:Person
    389 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
    390 schema:familyName Carvajal
    391 schema:givenName Richard D.
    392 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
    393 rdf:type schema:Person
    394 sg:person.0773073433.54 schema:affiliation grid-institutes:grid.152326.1
    395 schema:familyName Reinfeld
    396 schema:givenName Bradley
    397 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773073433.54
    398 rdf:type schema:Person
    399 sg:pub.10.1007/s00262-017-1968-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083869140
    400 https://doi.org/10.1007/s00262-017-1968-0
    401 rdf:type schema:CreativeWork
    402 sg:pub.10.1007/s00262-018-2131-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101243015
    403 https://doi.org/10.1007/s00262-018-2131-2
    404 rdf:type schema:CreativeWork
    405 sg:pub.10.1007/s00262-018-2169-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103849539
    406 https://doi.org/10.1007/s00262-018-2169-1
    407 rdf:type schema:CreativeWork
    408 sg:pub.10.1038/ncomms10391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037507717
    409 https://doi.org/10.1038/ncomms10391
    410 rdf:type schema:CreativeWork
    411 sg:pub.10.1038/ni.2703 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009839834
    412 https://doi.org/10.1038/ni.2703
    413 rdf:type schema:CreativeWork
    414 sg:pub.10.1038/nm.4308 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084129252
    415 https://doi.org/10.1038/nm.4308
    416 rdf:type schema:CreativeWork
    417 sg:pub.10.1038/s41467-021-23324-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138205161
    418 https://doi.org/10.1038/s41467-021-23324-4
    419 rdf:type schema:CreativeWork
    420 sg:pub.10.1038/s41586-019-0878-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1111628922
    421 https://doi.org/10.1038/s41586-019-0878-z
    422 rdf:type schema:CreativeWork
    423 sg:pub.10.1038/s41586-021-03442-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136982540
    424 https://doi.org/10.1038/s41586-021-03442-1
    425 rdf:type schema:CreativeWork
    426 sg:pub.10.1038/s41587-021-01021-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141957771
    427 https://doi.org/10.1038/s41587-021-01021-3
    428 rdf:type schema:CreativeWork
    429 sg:pub.10.1038/s41591-020-01188-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135200513
    430 https://doi.org/10.1038/s41591-020-01188-3
    431 rdf:type schema:CreativeWork
    432 sg:pub.10.1038/s41591-020-01211-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135201485
    433 https://doi.org/10.1038/s41591-020-01211-7
    434 rdf:type schema:CreativeWork
    435 sg:pub.10.1038/s41591-020-01224-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135436665
    436 https://doi.org/10.1038/s41591-020-01224-2
    437 rdf:type schema:CreativeWork
    438 sg:pub.10.1038/s41591-021-01406-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139508327
    439 https://doi.org/10.1038/s41591-021-01406-6
    440 rdf:type schema:CreativeWork
    441 sg:pub.10.1038/s43018-020-00133-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132441751
    442 https://doi.org/10.1038/s43018-020-00133-0
    443 rdf:type schema:CreativeWork
    444 sg:pub.10.1186/1471-2407-13-564 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048277702
    445 https://doi.org/10.1186/1471-2407-13-564
    446 rdf:type schema:CreativeWork
    447 sg:pub.10.1186/s12967-020-02573-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131947293
    448 https://doi.org/10.1186/s12967-020-02573-9
    449 rdf:type schema:CreativeWork
    450 sg:pub.10.1186/s12967-021-02798-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136806668
    451 https://doi.org/10.1186/s12967-021-02798-2
    452 rdf:type schema:CreativeWork
    453 sg:pub.10.1186/s40425-018-0331-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103128553
    454 https://doi.org/10.1186/s40425-018-0331-0
    455 rdf:type schema:CreativeWork
    456 sg:pub.10.1186/s40425-019-0771-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123477510
    457 https://doi.org/10.1186/s40425-019-0771-1
    458 rdf:type schema:CreativeWork
    459 sg:pub.10.1186/s40425-019-0786-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122758482
    460 https://doi.org/10.1186/s40425-019-0786-7
    461 rdf:type schema:CreativeWork
    462 grid-institutes:None schema:alternateName Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany
    463 Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS “Fondazione G. Pascale”, Naples, Italy
    464 Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France
    465 schema:name Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany
    466 Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS “Fondazione G. Pascale”, Naples, Italy
    467 Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France
    468 rdf:type schema:Organization
    469 grid-institutes:grid.137628.9 schema:alternateName New York Grossman School of Medicine, New York University Langone, New York, NY, USA
    470 Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA
    471 schema:name New York Grossman School of Medicine, New York University Langone, New York, NY, USA
    472 Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA
    473 rdf:type schema:Organization
    474 grid-institutes:grid.152326.1 schema:alternateName Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA
    475 schema:name Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA
    476 rdf:type schema:Organization
    477 grid-institutes:grid.170205.1 schema:alternateName Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA
    478 schema:name Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA
    479 rdf:type schema:Organization
    480 grid-institutes:grid.19006.3e schema:alternateName Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    481 schema:name Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    482 rdf:type schema:Organization
    483 grid-institutes:grid.239585.0 schema:alternateName Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
    484 schema:name Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
    485 rdf:type schema:Organization
    486 grid-institutes:grid.240324.3 schema:alternateName New York University Langone Medical Center, New York, NY, USA
    487 schema:name New York University Langone Medical Center, New York, NY, USA
    488 rdf:type schema:Organization
    489 grid-institutes:grid.240531.1 schema:alternateName Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA
    490 schema:name Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA
    491 rdf:type schema:Organization
    492 grid-institutes:grid.240614.5 schema:alternateName Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
    493 schema:name Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
    494 rdf:type schema:Organization
    495 grid-institutes:grid.264727.2 schema:alternateName Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA
    496 schema:name Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA
    497 rdf:type schema:Organization
    498 grid-institutes:grid.32224.35 schema:alternateName Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    499 schema:name Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    500 rdf:type schema:Organization
    501 grid-institutes:grid.411266.6 schema:alternateName Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France
    502 schema:name Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France
    503 rdf:type schema:Organization
    504 grid-institutes:grid.411326.3 schema:alternateName Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
    505 schema:name Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
    506 rdf:type schema:Organization
    507 grid-institutes:grid.430814.a schema:alternateName Netherlands Cancer Institute, Amsterdam, Netherlands
    508 schema:name Netherlands Cancer Institute, Amsterdam, Netherlands
    509 rdf:type schema:Organization
    510 grid-institutes:grid.48336.3a schema:alternateName Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA
    511 Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA
    512 schema:name Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA
    513 Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA
    514 rdf:type schema:Organization
    515 grid-institutes:grid.488730.0 schema:alternateName Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA
    516 schema:name Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA
    517 rdf:type schema:Organization
    518 grid-institutes:grid.508451.d schema:alternateName Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy
    519 Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori “Fondazione Pascale” IRCCS, Naples, Italy
    520 schema:name Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy
    521 Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori “Fondazione Pascale” IRCCS, Naples, Italy
    522 rdf:type schema:Organization
    523 grid-institutes:grid.516104.7 schema:alternateName Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA
    524 schema:name Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA
    525 rdf:type schema:Organization
    526 grid-institutes:grid.83440.3b schema:alternateName Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK
    527 schema:name Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK
    528 rdf:type schema:Organization
    529 grid-institutes:grid.8515.9 schema:alternateName Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
    530 schema:name Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
    531 rdf:type schema:Organization
    532 grid-institutes:grid.9851.5 schema:alternateName UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland
    533 schema:name UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland
    534 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...